A6927 • 2025

Relates to prescription labels for gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic steroids, alpha reductase inhibitors, progestins, or drug classes for hormone replacement therapy

Passed Legislature

This bill passed both chambers and reached final enrollment, even if later executive action is not shown here.

Sponsor: Tony Simone
Last action: 2026-05-28
Official status: In Assembly Committee
Effective date: Not listed

Plain English Breakdown

Using official source text because the generated explanation was unavailable or could not be confirmed against the official bill text.

Relates to prescription labels for gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic steroids, alpha reductase inhibitors, progestins, or drug classes for hormone replacement therapy

Relates to prescription labels for gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic steroids, alpha reductase inhibitors, progestins, or drug classes for hormone replacement therapy Provides that prescription labels for gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic steroids, alpha reductase inhibitors, progestins, or drug classes for hormone replacement therapy maybe include the name of the dispensing practice instead of the prescriber; provides for notice to patients.

What This Bill Does

Relates to prescription labels for gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic steroids, alpha reductase inhibitors, progestins, or drug classes for hormone replacement therapy Provides that prescription labels for gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic steroids, alpha reductase inhibitors, progestins, or drug classes for hormone replacement therapy maybe include the name of the dispensing practice instead of the prescriber; provides for notice to patients.

Limits and Unknowns

This entry is temporarily using official source text because the generated explanation could not be confirmed against the official bill text during the last sync.

Bill History

2026-05-28 Assembly
AMEND (T) AND RECOMMIT TO HIGHER EDUCATION
2026-05-28 Assembly
PRINT NUMBER 6927A
2026-01-07 Assembly
REFERRED TO HIGHER EDUCATION
2025-03-18 Assembly
REFERRED TO HIGHER EDUCATION

Official Summary Text

Relates to prescription labels for gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic steroids, alpha reductase inhibitors, progestins, or drug classes for hormone replacement therapy
Provides that prescription labels for gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic steroids, alpha reductase inhibitors, progestins, or drug classes for hormone replacement therapy maybe include the name of the dispensing practice instead of the prescriber; provides for notice to patients.

Current Bill Text

Read the full stored bill text

S T A T E   O F   N E W   Y O R K
        ________________________________________________________________________

                                          6927

                               2025-2026 Regular Sessions

                                  I N  A S S E M B L Y

                                     March 18, 2025
                                       ___________

        Introduced by M. of A. SIMONE -- read once and referred to the Committee
          on Higher Education

        AN ACT to amend the education law and the public health law, in relation
          to prescription labels for mifepristone, misoprostol, gonadotropin-re-
          leasing  hormone  agonists,  pubertal suppressants, anabolic steroids,
          alpha reductase inhibitors, progestins, or drug  classes  for  hormone
          replacement therapy for treatment of gender dysphoria

          THE  PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM-
        BLY, DO ENACT AS FOLLOWS:

     1    Section 1. Paragraph b-1 of subdivision  1  of  section  6807  of  the
     2  education  law, as added by chapter 7 of the laws of 2025, is amended to
     3  read as follows:
     4    b-1. Notwithstanding paragraph b of  this  section,  the  prescription
     5  label  for  mifepristone,  misoprostol, [and their generic alternatives]
     6  GONADOTROPIN-RELEASING HORMONE AGONISTS, PUBERTAL SUPPRESSANTS, ANABOLIC
     7  STEROIDS, ALPHA REDUCTASE INHIBITORS, PROGESTINS, OR  DRUG  CLASSES  FOR
     8  HORMONE  REPLACEMENT  THERAPY  FOR  TREATMENT  OF  GENDER DYSPHORIA, may
     9  include the name OR ADDRESS  of  the  dispensing  health  care  practice
    10  instead of the name of the dispenser.
    11    § 2. Subdivision 1-a of section 6810 of the education law, as added by
    12  chapter 7 of the laws of 2025, is amended to read as follows:
    13    1-a.   Notwithstanding   subdivision  one  of  this  section,  at  the
    14  prescriber's request, the prescription label for mifepristone, misopros-
    15  tol, [and their  generic  alternatives]  GONADOTROPIN-RELEASING  HORMONE
    16  AGONISTS,  PUBERTAL  SUPPRESSANTS,  ANABOLIC  STEROIDS,  ALPHA REDUCTASE
    17  INHIBITORS, PROGESTINS, OR DRUG CLASSES FOR HORMONE REPLACEMENT  THERAPY
    18  FOR TREATMENT OF GENDER DYSPHORIA, may include the name of the prescrib-
    19  ing health care practice instead of the name of the prescriber.
    20    § 3. The public health law is amended by adding a new section 280-d to
    21  read as follows:

         EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                              [ ] is old law to be omitted.
                                                                   LBD10852-01-5
        A. 6927                             2

     1    §  280-D.  PATIENT NOTIFICATION OF PRESCRIPTION LABEL CHANGE. A HEALTH
     2  CARE PRESCRIBER SHALL INFORM THE PATIENT IF SUCH PRESCRIBER HAS INCLUDED
     3  OR HAS REQUESTED TO INCLUDE THE  NAME  OR  ADDRESS  OF  THE  PRESCRIBING
     4  HEALTH  CARE  PRACTICE  INSTEAD  OF  THE  NAME OF SUCH PRESCRIBER ON THE
     5  PRESCRIPTION  LABEL  WHEN PRESCRIBING MIFEPRISTONE, MISOPROSTOL, GONADO-
     6  TROPIN-RELEASING HORMONE AGONISTS, PUBERTAL SUPPRESSANTS, ANABOLIC STER-
     7  OIDS, ALPHA  REDUCTASE  INHIBITORS,  PROGESTINS,  OR  DRUG  CLASSES  FOR
     8  HORMONE REPLACEMENT THERAPY FOR TREATMENT OF GENDER DYSPHORIA.
     9    § 4. This act shall take effect immediately.